Back to top

Image: Bigstock

MediWound (MDWD) Surges 18.2%: Is This an Indication of Further Gains?

Read MoreHide Full Article

MediWound (MDWD - Free Report) shares soared 18.2% in the last trading session to close at $10.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 9.7% gain over the past four weeks.

This marks the third consecutive day of MediWound’s price increase since it announced that the U.S. Department of Defensehas awarded MediWound additional funding to develop NexoBrid as a non-surgical solution for field-care burn treatment for the U.S. Army.

This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.43 per share in its upcoming report, which represents a year-over-year change of +52.8%. Revenues are expected to be $4.82 million, down 17% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For MediWound, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MDWD going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

MediWound belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Corcept Therapeutics (CORT - Free Report) , closed the last trading session 1.9% higher at $32.99. Over the past month, CORT has returned -1.5%.

Corcept's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.20. Compared to the company's year-ago EPS, this represents a change of -33.3%. Corcept currently boasts a Zacks Rank of #2 (Buy).

See More Zacks Research for These Tickers

Normally $25 each - click below to receive one report FREE:

Corcept Therapeutics Incorporated (CORT) - free report >>

MediWound Ltd. (MDWD) - free report >>

Published in